Skip to main content
Equibles
IRWD logo

IRWD · Ironwood Pharmaceuticals Inc

Track IRWD — free

Use IRWD with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about IRWD

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$4.31 +0.23 (+5.64%) At close · Aug 14
Market Cap
$712.18M
Shares
165.24M

Ironwood Pharmaceuticals Inc Earnings Call Transcripts

Every quarterly earnings call for Ironwood Pharmaceuticals Inc (IRWD) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲0.4% $117.13M $41.37M '21 Q4 22-02-17 ▲9.8% $97.53M $38.80M '22 Q1 22-05-05 ▼6.5% $97.23M $37.08M '22 Q2 22-08-04 ▲4.7% $108.64M $50.32M '22 Q3 22-11-03 ▼8.5% $107.20M $48.87M '22 Q4 23-02-16 ▲6.7% $104.06M $45.71M '23 Q1 23-05-22 ▲10.4% $107.38M −$1.06B '23 Q2 23-08-08 ▲4.7% $113.74M $15.32M '23 Q3 23-11-09 ▲9.7% $117.55M −$1.09M '23 Q4 24-02-15 ▼28% $74.88M −$4.16M '24 Q1 24-05-09 ▼12.1% $94.40M −$860,000 '24 Q2 24-08-08 ▼19.5% $91.59M $3.65M '24 Q3 24-11-07 ▼23% $90.55M $2.26M '24 Q4 25-02-27 ▼47.3% $47.71M −$2.28M '25 Q4 26-02-25 ▲158.9% $106.51M $40.77M '26 Q1 26-05-07 LATEST ▲32.6% $113.04M $51.29M '26 Q2 26-08-06
Earnings call
FY26 · Q2
2026-08-06
Ironwood Pharmaceuticals Inc Q2 FY2026 Earnings Call
Revenue
$113.04M
▲ 32.6% YoY
Diluted EPS
$0.31
▲ 121.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-04
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Ironwood Pharmaceuticals Inc Q1 FY2026 Earnings Call
Confident tone Apraglutide / SBS-IF opportunity Linzess commercial performance Pricing and gross-to-net dynamics
Revenue
$106.51M
▲ 158.9% YoY
Diluted EPS
$0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Ironwood Pharmaceuticals Inc Q4 FY2025 Earnings Call
Confident tone Aproglutide STARS II confirmatory Phase III trial LINZESS commercial performance and market leadership 2026 financial guidance and EBITDA growth
Revenue
$47.71M
▼ 47.3% YoY
Diluted EPS
$-0.01
▼ 200% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q4
2025-02-27
Ironwood Pharmaceuticals Inc Q4 FY2024 Earnings Call
Positive tone Short bowel syndrome commercial opportunity Apraglutide NDA progress LINZESS franchise
Revenue
$90.55M
▼ 23% YoY
Diluted EPS
$0.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Ironwood Pharmaceuticals Inc Q3 FY2024 Earnings Call
Positive tone LINZESS commercial performance Apraglutide NDA and launch Profit and cash flow maximization
Revenue
$91.59M
▼ 19.5% YoY
Diluted EPS
$0.02
▼ 77.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Ironwood Pharmaceuticals Inc Q2 FY2024 Earnings Call
Positive tone LINZESS prescription demand Apraglutide NDA submission Apraglutide clinical profile and STARS Phase 3
Revenue
$94.40M
▼ 12.1% YoY
Diluted EPS
$-0.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Ironwood Pharmaceuticals Inc Q1 FY2024 Earnings Call
Confident tone Apraglutide Phase III STARS results LINZESS commercial performance Apraglutide regulatory and launch planning
Revenue
$74.88M
▼ 28% YoY
Diluted EPS
$-0.03
▼ 112% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Ironwood Pharmaceuticals Inc Q4 FY2023 Earnings Call
Confident tone Apraglutide / STARS Phase 3 in short bowel syndrome LINZESS commercial performance Pipeline catalysts and upcoming data readouts
Revenue
$117.55M
▲ 9.7% YoY
Diluted EPS
$-0.01
▼ 103.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Ironwood Pharmaceuticals Inc Q3 FY2023 Earnings Call
Revenue
$113.74M
▲ 4.7% YoY
Diluted EPS
$0.09
▼ 67.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Ironwood Pharmaceuticals Inc Q2 FY2023 Earnings Call
Revenue
$107.38M
▲ 10.4% YoY
Diluted EPS
$-6.84
▼ 3357.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-22
Ironwood Pharmaceuticals Inc Q1 FY2023 Earnings Call
Revenue
$104.06M
▲ 6.7% YoY
Diluted EPS
$0.25
▲ 19% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-16
Ironwood Pharmaceuticals Inc Q4 FY2022 Earnings Call
Revenue
$107.20M
▼ 8.5% YoY
Diluted EPS
$0.27
▲ 8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Ironwood Pharmaceuticals Inc Q3 FY2022 Earnings Call
Revenue
$108.64M
▲ 4.7% YoY
Diluted EPS
$0.28
▼ 17.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Ironwood Pharmaceuticals Inc Q2 FY2022 Earnings Call
Revenue
$97.23M
▼ 6.5% YoY
Diluted EPS
$0.21
▼ 91.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Ironwood Pharmaceuticals Inc Q1 FY2022 Earnings Call
Revenue
$97.53M
▲ 9.8% YoY
Diluted EPS
$0.21
▼ 16% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-17
Ironwood Pharmaceuticals Inc Q4 FY2021 Earnings Call
Revenue
$117.13M
▲ 0.4% YoY
Diluted EPS
$0.25
▼ 7.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Ironwood Pharmaceuticals Inc Q3 FY2021 Earnings Call
Revenue
$103.75M
▲ 0.3% YoY
Diluted EPS
$0.34
▲ 61.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Ironwood Pharmaceuticals Inc Q2 FY2021 Earnings Call
Revenue
$104.03M
▲ 16.3% YoY
Diluted EPS
$2.39
▲ 1393.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Ironwood Pharmaceuticals Inc Q1 FY2021 Earnings Call
Revenue
$88.84M
▲ 11.1% YoY
Diluted EPS
$0.25
▲ 1150% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-17
Ironwood Pharmaceuticals Inc Q4 FY2020 Earnings Call
Revenue
$116.68M
▼ 7.6% YoY
Diluted EPS
$0.27
▼ 10% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Ironwood Pharmaceuticals Inc Q3 FY2020 Earnings Call
Revenue
$103.47M
▼ 21.1% YoY
Diluted EPS
$0.21
▲ 61.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Ironwood Pharmaceuticals Inc Q2 FY2020 Earnings Call
Revenue
$89.43M
▼ 12.5% YoY
Diluted EPS
$0.16
▲ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Ironwood Pharmaceuticals Inc Q1 FY2020 Earnings Call
Revenue
$79.94M
▲ 16.3% YoY
Diluted EPS
$0.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–24 of 24 earnings calls
Key facts CIK 1446847 CUSIP 46333X108 13F (30d) 208 filings 201 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)